Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Disclosed is a method of inhibiting anandamide amidase in an individual or animal and novel inhibitors of anandamide amidase. The disclosed method and novel compounds can be used to reduce pain in an individual or animal suffering from pain, reducing nausea in an individual undergoing chemotherapy, for example cancer chemotherapy, suppressing appetite in an individual, reducing intraocular pressure in the eye of an individual or animal suffering from glaucoma and suppressing the immune system in an individual with an organ transplant.

Abstract: A process and intermediates for preparing .alpha.

Abstract: The present invention relates to a compound of the formula: ##STR1## wherein Ar represents an optionally substituted aromatic group; Q represents a divalent aliphatic hydrocarbon group; R.sub.1 represents hydrogen, cyano, an optionally substituted hydrocarbon group, a group of the formula: ##STR2## wherein R.sup.3 and R.sub.4 independently represent hydrogen, acyl or an optionally substituted hydrocarbon group, or R.sup.3 and R.sup.4 jointly form a ring, or acyl; R.sup.2 represents acyl; ......... represents a single bond or a double bond; m represents 1 or 2 or a salt, a process of producing thereof and an anti-neurodegenerative composition.

Abstract: Process for the preparation of N-alkyl-N,O-diacetyl hydroxylamine, for instance N-methyl-N,O-diacetyl hydroxylamine, by catalytic reduction of a nitroalkane, for instance nitromethane, in the presence of acetic anhydride. As catalyst preferably a platinum on alumina catalyst is used. The invention provides a simple one-step process for the preparation of N-alkyl-N,O-diacetyl hydroxylamine in a relatively concentrated reaction medium.

Abstract: The invention relates to fluid resuscitation of the human or animal body by administration of deferoxamine (DFO) and a water-soluble biopolymer.The DFO and the biopolymer are preferably bonded together.The biopolymer may be a polysaccharide or a protein.The DFO and the biopolymer are preferably formulated as an aqueous solution suitable for oral administration.The fluid resuscitation may be effected for ameliorating systemic oxidant injury occurring during ischemia and subsequent reperfusion.The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived from combustion, hemorrhagic shock and other types of trauma.

Abstract: Describes a process for preparing N,O-disubstituted hydroxylamine compounds comprising reacting an aqueous solution of free hydroxylamine with an equimolar amount of a carbonyl halide-containing compound, e.g., a chloroformate such as phenyl chloroformate, in the presence of a substantially stoichiometric amount of a weak inorganic basic reagent, thereby to produce the N-substituted derivative, and thereafter further reacting an inert organic solvent solution of the N-substituted derivative with an equimolar amount of the corresponding carbonyl halide-containing compound in the presence of a substantially stoichiometric amount of weak inorganic basic reagent, thereby to produce the N,O-disubstituted derivative, e.g., N,O-bis(phenoxycarbonyl) hydroxylamine. In a preferred embodiment, the organic solvent is used also in the reaction that produces the N-substituted derivative. N,O-disubstituted hydroxylamine compounds containing less than 3 weight percent, e.g., less than 0.

Abstract: There are provided hydroxamic acids, and the esters and chelates thereof having the structure ##STR1## and their use for the prevention, control or amelioration of diseases caused by phytopathogenic fungi. Further provided are compositions and methods comprising those compounds for the protection of plants from fungal infestation and disease.

Abstract: Compounds of the structure ##STR1## where M is a pharmaceutically acceptable cation or a metabolically cleavable group, R is alkyl, cycloalkyl or --NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted alkyl, cycloalkyl, carbocyclic aryl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.

Abstract: Tricyclic hydroxyurea and hydroxamate compounds, pharmaceutical compositions, and their use as as inhibitors of the oxidation of polyunsaturated fatty acids, such as by inhibition on the 5-lipoxygenase enzyme, and treatment of diseases therein.

Abstract: The solution pertains to hydrolytically degradable hydrophilic gels consisting of the individual chains of hydrophilic polymer interconnected with crosslinks containing the structure unit ##STR1## The method for preparation of the hydrolytically degradable gels consists in subjecting hydrophilic monomers or their mixture to the radical polymerization or copolymerization, or to copolymerization with hydrophobic monomers, in the presence of a new compound--N,O-dimethacryloylhydroxylamine--as a crosslinking agent, and, if desired, in the presence of a solvent, whereas the amount of hydrophilic monomers is 50 to 99.8 molar percent related to all monomers present.

Abstract: The present invention relates to N,O-diacyl,N-acyl hydroxylamines and their use as bleach activators in conjunction with oxygen-releasing compounds.

Abstract: Compounds of the formula: ##STR1## where R.sub.1 is amino or methyl; R.sub.2 is C.sub.1 -C.sub.2 alkyl; R.sub.3 is one or more substituents selected from hydrogen, halogen or trihalomethyl; R.sub.4 is one or more substituents selected from hydrogen, halogen, trihalomethyl, C.sub.1 to C.sub.4 alkoxy or C.sub.1 to C.sub.4 alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.6 alkoyl are inhibitors of 5- and/or 12-lipoxygenase enzymes.